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RESULTS AND DISCUSSION
Solid state analysis (Fig. 3-4) reveals that printing the drug alone results in a fully crystalline product,
however on application of a polymer this crystallinity is reduced with a completely amorphous
product being achieved by 75% polymer content or higher.
The morphology noticeably changes on printing with the polymer with the needle crystals of the
API gradually forming spherical amorphous particles as the polymer forms a matrix around the drug
(Fig. 5).
Printer capabilities tests on the HPLC (Fig. 6) show a linear, reproducible relationship between mass
and deposition size, mass and layer number and mass and nozzle size. Speed was also analysed but
was found to be much less linear overall. At the lower speeds, the ink seemed more prone to
blocking the printer, while the higher speeds seemed to result in too little time for sufficient
deposition to occur.
Dissolution testing (Fig. 7) so far shows increased drug release and intrinsic dissolution rates from
the printed samples relative to comparable physical mixtures, which is believed to be due to greater
control over drug content and distribution, and reduced crystallinity.
MATERIALS AND METHODS
Dosage forms were produced using an Optomec AJ200 Inkjet 3D Printer (Fig. 1), which functions by aerosol jet powered by pneumatic atomisation. Pressurised nitrogen is forced through API and/or
polymer based solutions causing this “ink” to form a vapour which ultimately transverses a ceramic nozzle tip in a jet stream. The formulation "ink" can be deposited on an appropriate substrate in a similar
manner to how ink is applied to paper in a conventional home printer. The printer allows scaling of the formulation at a number of points. This can be achieved firstly at the design stage, in which CAD
drawings can be used as a template, secondly by changing the ink ratio or components, thirdly by changing the nozzle diameter utilised and ultimately by building formulations up in layers. This printer has
never been used in pharmaceutical manufacture previously and as such anything we can achieve is highly innovative [1-2].
Solid state analysis was carried out by powder x-ray diffraction, scanning electron microscopy and Raman spectroscopy. This allowed comparisons to be made between the powdered materials and the
printed ones, and also between the API alone and with varying concentrations of a polymer present. Content analysis and printer capabilities were analysed by HPLC using a validated method of 80:20
acetonitrile: acidified water at 1 ml per minute on a C-18(2) 100Å silica reversed phase column. Samples were tested for the effects of speed, deposition size, layering and nozzle size, when compared to a
control of a 5 mm diameter circle deposition, created at 3 mm/s using a 250 µm nozzle. Due to the size of the formulations dissolution was analysed using the innovative method of surface dissolution
imaging as standard USP methods proved inadequate. Samples were subjected to UV light passed through a filter of suitable wavelength as simulated intestinal fluid passed over the surface (Fig. 2). The UV
images were detected on a computer and from this drug release and intrinsic dissolution could be ascertained.
Fig. 1: Inkjet printing using an Optomec AJ200 Inkjet Printer. Images obtained from Optomec Ltd. [3]
Light Source
Fig 2: Surface Dissolution Imaging is achieved by shining UV light through a sample chamber within a quartz cell to image the release of the drug
from the surface as media is passed over the sample. The image is then collected in real time using computer software.
INTRODUCTION
Oral drug delivery is currently the preferred method of administration, however, the problem of poor solubility means many drugs are not ideally suited to this [1]. Although a number of methods to
increase solubility already exist, there is a need for less damaging methods of production which are more flexible to the needs of the patient. With a view to reducing the risk of degradation and negative
polymorphic changes, the potentially damaging steps of granulation, drying and compression will be replaced with the innovative formulation technique of inkjet printing. Inkjet printing has the capacity to
produce highly precise dosing in a continuous manner and affords a degree of flexibility in that dosage forms can be designed on a computer and thus are fully scalable. Overall, the current work aims to
increase the solubility of poorly soluble drugs using the innovative manufacturing technique of inkjet printing with a view to creating formulations which are more easily tailored to the needs of the patient.
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CONCLUSIONS
Ultimately it has been established that printing the BCS Class II drug alone results in a crystalline product but on addition of a polymer this crystallinity is reduced and it is possible to print solid dispersions
which are fully amorphous. Printing has also allowed greater control over drug distribution, which has allowed improved solubility overall. Additionally, the printer has proved itself capable of producing
scalable products with a view to more patient centric dosage form manufacture.
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Fig 3: XRD of physical mixtures (A, C, E, G and I) and
printed samples (B, D, F, H and J) in the following ratios:
A) and B) API alone, C) and D)1:1; E) and F) 1:2, G) and
H)1:3 I) and J) 1:4 API:polymer.
Fig 4: Raman spectroscopy of the terahertz (top) 1500-
1650 cm-1 (bottom) and 3050-3100 cm-1 (middle)
regions of the drug as its crystalline powder form
(black) and as part of a solid dispersion (red)
Fig 5: SEM of printed samples: API (top left) and premixed API and polymer 1:1 (top middle), 1:2 (top right), 1:3
(bottom left), 1:4 (bottom right) , 1.5K magnification
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Fig 6: Effects of nozzle size (top left), area of deposition (top right), number of layers (bottom left) and speed
(bottom right) on mass, n=6 ±SE
Fig. 7: Intrinsic Dissolution Rate (Left) and Drug Release (Right) values obtained from Surface Dissolution Imaging on
compacts (top) and printed samples (bottom) of API alone (green), and 1:1 (red), 1:2 (purple), 1:3 (blue) and 1:4
(orange) API: polymer w/w, n=3 ±SE.
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